Technology

Dr. Varshney discusses how AI is being used to sort data and discover new molecules and indications for existing drugs.

Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.

How pharmaceutical companies can utilize AI at key stages of the treatment journey to enhance patient-centric engagement by increasing empathy and humanity in patient interactions.

The CTO of Authenticx discusses preventing bias from becoming part of AI models.

Craig Tooman, CEO of Silence Therapeutics, on steering through the rough biotech funding and investment waters post-pandemic—and how a retooled organizational approach has the company in a stronger position today in the growing field of gene silencing through siRNA drugs.

BioXcel’s VP of AI drug discovery discusses how use of the technology has advanced in the past year.

Both systems are over-the-counter products that provide continuous glucose monitoring.

How AI Can Improve Engagement with Healthcare Professionals (HCPs).

The CEO of AION Labs discusses both the new ways that AI is being implemented in drug development and why Israel is becoming the center of AI development in the pharma industry.

In an interview with Pharm Exec Associate Editor Don Tracy at Financial Times’ US Pharma and Biotech Summit, Tala Fakhouri, Associate Director for Policy Analysis, FDA, discusses the use of artificial intelligence and machine learning in drug development.

The platform will use AI technology to provide pharmacists with more tools.

A greater shift from paper records and physical assets is achievable.

Webinar Date/Time: Wednesday, June 12th, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

The vice president of technology strategy & strategic partnerships at Syneos Health discusses how new digital technologies are changing the ways that data is collected, shared, analyzed.

AI allows patients, doctors, and payers to make informed decisions based on evidence at a much faster pace.

In an interview with Pharm Exec Associate Editor Don Tracy, Alessandro Zannini, Global After-Sales Manager, Stevanato Group discusses the benefits of generative artificial intelligence.

Rahman discusses the new opportunities that digital twins present to researchers.

The Health Cube will increase remote and virtual care options for populations living in remote areas.

Butta discusses how new technologies are being implemented in at-home devices.

Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.

The meeting is scheduled for May in Switzerland.

Webinar Date/Time: Thursday, May 23, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Webinar Date/Time: Thursday, May 9, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Webinar Date/Time: Thursday, April 18, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Precision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.

Although life science organizations are not immune to the benefits of artificial intelligence, it’s important to integrate it with caution because there is no “one-size fits all” approach.

Anderson discusses how AI can be used to take data collected by different processes and bring it into a usable format.

Webinar Date/Time: Thursday, March 21, 2024 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET

A Harvard Business School Healthcare Alumni Association (HBSHAA) Q&A with Professor Deborah Ancona, founder of the MIT Leadership Center.

While no company has yet achieved the full promise of AI to radically accelerate time to market, meaningful strides are being made across the drug discovery funnel.